IC
OLMA icon

Ikarian Capital’s Olema Pharmaceuticals OLMA Stock Holding History

Ikarian Capital’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.2M Buy
549,800
+349,800
+175% +$7.79M 0.67% 41
2025
Q4 		$5M Buy
+200,000
New +$3.56M 0.39% 63

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Ikarian Capital's OLMA Position: Q1 2026 in Review

Ikarian Capital reduced its Olema Pharmaceuticals (OLMA) stake by 21% in Q1 2026, selling an estimated $3.57M and leaving 598,281 shares worth $8.92M. The position accounts for 0.72% of the portfolio, ranked #37.

Ikarian Capital first reported a position in OLMA in Q3 2024 and has held it in 5 quarters since. The position peaked at $19M in Q4 2025. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • Ikarian Capital held 598,281 shares of Olema Pharmaceuticals worth $8.92M as of Q1 2026.
  • Ikarian Capital sold 160,373 Olema Pharmaceuticals shares in Q1 2026, an estimated $3.57M.
  • Olema Pharmaceuticals made up 0.72% of Ikarian Capital's portfolio in Q1 2026, its #37 holding.
  • Ikarian Capital first reported a position in Olema Pharmaceuticals in Q3 2024 and has held it in 5 quarters since.
  • Ikarian Capital's Olema Pharmaceuticals position peaked at $19M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.